What is Metagenomi, Inc. Common Stock?
an in vivo genome editing company, develops curative genetic medicines in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 26.15M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 0 |
| 6-9months | 11,581 shares $3k | 0 |
| 9-12months | 25,406 shares $10k | 0 |